|
Product Details:
|
| Specification: | 5mg, 10mg, 20mg | Molecular Weight: | 579.1 |
|---|---|---|---|
| Dosage Usage: | Oral | Execution Standard: | USP42 |
| Other Names: | Clomifene Citrate | Molecular Formula: | C23H32N6O4S |
USP42 Pharmaceutical Capsule Sex Enhancement Powder Vardenafil Hydrochloride Tablets
Some medical conditions may interact with vardenafil. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
if you are pregnant, planning to become pregnant, or are breast-feeding
if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
if you have allergies to medicines, foods, or other substances
if you have a deformed penis (eg, cavernosal fibrosis, Peyronie disease), blood cell problems (eg, leukemia, multiple myeloma, sickle cell anemia), or any other condition that may increase the risk of a prolonged erection (priapism)
if you have a history of a prolonged (more than 4 hours) or painful erection (priapism)
if you have a history of certain eye problems (eg, macular degeneration, optic neuropathy, retinitis pigmentosa, sudden vision loss) or hearing problems (eg, ringing in the ears, decreased hearing, hearing loss)
if you have a history of liver or kidney problems, dialysis, high or low blood pressure, ulcers, seizures, lung problems (eg, pulmonary veno-occlusive disease), bleeding problems, blood vessel problems, or heart problems (eg, angina, aortic stenosis, heart failure)
if you have a history of heart attack, stroke, a certain type of irregular heartbeat (long QT syndrome), or a family history of long QT syndrome
How should I take vardenafil?
Staxyn (vardenafil disintegrating tablets) should not be used in place of Levitra (vardenafil regular tablets). Avoid medication errors by using only the form and strength your doctor prescribes.
Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed.
CERTIFICATE OF ANALYSIS |
||
| Test Items | Specification | Test Results |
| Description | White or almost white crystalline powder | White crystalline powder |
| Melting Point | 191.0~193.0ºC | 192° |
| Loss of drying | ≤1.0% | 0.50% |
| Heavy Metal | ≤20ppm | 15ppm |
| TLC | Only one spot | Only one spot |
| Assay | ≥99.5% | 99.91% |
Three selective phosphodiesterase type 5 (PDE5) inhibitors: sildenafil (Cialis), vardenafil (Eride), and tadalafil are all first-line agents for ED; In terms of efficacy, safety and tolerability, PDE5 inhibitors were not significantly different from apomorphine; Intracavernous injection of prostaglandin E1 is a second-line treatment for ED; Intraurethral administration of prostaglandin E1 is less effective than intracavernous injection of prostaglandin E1. It is concluded that PDE5 inhibitors have the characteristics of effectiveness, good tolerability and safety in the treatment of ED. Apomorphine, intracavernous prostaglandin E1, and intraurethral administration of prostaglandin E1 are also effective and well tolerated.
Contact Person: 张国庆
Tel: +861314804998
